Barclays’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.24M Buy
216,646
+2,040
+1% +$30.5K ﹤0.01% 1911
2025
Q1
$3.46M Buy
214,606
+91,535
+74% +$1.48M ﹤0.01% 1660
2024
Q4
$2.87M Buy
123,071
+17,604
+17% +$410K ﹤0.01% 1978
2024
Q3
$3.1M Buy
105,467
+41,424
+65% +$1.22M ﹤0.01% 1863
2024
Q2
$1.51M Buy
64,043
+18,081
+39% +$425K ﹤0.01% 1884
2024
Q1
$1.74M Buy
45,962
+464
+1% +$17.6K ﹤0.01% 2039
2023
Q4
$979K Buy
+45,498
New +$979K ﹤0.01% 2611
2023
Q3
Sell
-4
Closed 4380
2023
Q2
$0 Hold
4
﹤0.01% 4410
2023
Q1
$0 Hold
4
﹤0.01% 4415
2022
Q4
$0 Hold
4
﹤0.01% 4515
2022
Q3
$0 Hold
4
﹤0.01% 4825
2022
Q2
$0 Sell
4
-262
-98% ﹤0.01% 4908
2022
Q1
$16K Sell
266
-1,700
-86% -$102K ﹤0.01% 4391
2021
Q4
$233K Buy
1,966
+1,305
+197% +$155K ﹤0.01% 2785
2021
Q3
$131K Buy
661
+434
+191% +$86K ﹤0.01% 3127
2021
Q2
$40K Sell
227
-1,291
-85% -$227K ﹤0.01% 3482
2021
Q1
$301K Buy
1,518
+929
+158% +$184K ﹤0.01% 2943
2020
Q4
$116K Sell
589
-196
-25% -$38.6K ﹤0.01% 2935
2020
Q3
$139K Sell
785
-140
-15% -$24.8K ﹤0.01% 2899
2020
Q2
$213K Buy
925
+578
+167% +$133K ﹤0.01% 2779
2020
Q1
$41K Sell
347
-712
-67% -$84.1K ﹤0.01% 3184
2019
Q4
$202K Buy
1,059
+514
+94% +$98K ﹤0.01% 3169
2019
Q3
$105K Sell
545
-143
-21% -$27.6K ﹤0.01% 3381
2019
Q2
$118K Buy
688
+189
+38% +$32.4K ﹤0.01% 3502
2019
Q1
$100K Buy
+499
New +$100K ﹤0.01% 3341
2018
Q4
Sell
-245
Closed -$59K 4363
2018
Q3
$59K Buy
245
+197
+410% +$47.4K ﹤0.01% 3682
2018
Q2
$13K Sell
48
-80
-63% -$21.7K ﹤0.01% 3812
2018
Q1
$32K Buy
+128
New +$32K ﹤0.01% 3699